MYOCARDIAL SUBSTRATE UTILIZATION IN EXPERIMENTAL SHOCK

J. J. Spitzer and L. B. Hinshaw

Prepared for Publication in Circulatory Shock

Department of Physiology, Louisiana State University Medical Center, New Orleans, Louisiana, and University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

19 July 1976

Reproduction in whole or in part is permitted for any purpose of the United States Government

Distribution of this report is unlimited
MYOCARDIAL SUBSTRATE UTILIZATION IN EXPERIMENTAL SHOCK

J. J. Spitzer and L. B. Hinshaw

Prepared for Publication

in

Circulatory Shock

Department of Physiology,
Louisiana State University Medical Center,
New Orleans, Louisiana,
and
University of Oklahoma Health Sciences Center,
Oklahoma City, Oklahoma

19 July 1976

Reproduction in whole or in part is permitted for any
purpose of the United States Government

Distribution of this report is unlimited
INTRODUCTION

It has been demonstrated by numerous investigations that under control postprandial conditions the myocardium may utilize a variety of substrates. Quantitatively, the most important of these are fatty acids and lactate. Under control conditions close to two-thirds of the myocardial energy is derived from oxidation of free fatty acids (FFA) and about one-third from the utilization of lactate. Since the arterial concentration of several metabolites changes during shock, and because of the dependence of myocardial substrate utilization on arterial concentration, it seemed desirable to study the alterations in myocardial substrate utilization during experimentally produced shock.

The results obtained in several shock models are summarized in this presentation. The following interventions were utilized to produce shock-like conditions experimentally: (a) administration of an LD$_{90}$ *Escherichia coli* endotoxin; (b) acute severe hemorrhage, (c) anaphylactic shock caused by horse serum administration, (d) severe hypotension caused by physostigmine infusion, (e) hyperlactacidemia caused by lactate infusion, and (f) prolonged hypoperfusion of the coronary arteries.

MATERIALS AND METHODS

Dogs anesthetized with sodium pentobarbarbital were used for all of the studies. In all experiments (with the exception of the coronary hypoperfusion studies) a systemic artery and the coronary sinus were catheterized for simultaneous blood sampling (1). Continuous infusion of albumin-bound, $[1-^{14}C]$ palmitate was administered 60 to 90 min before and throughout the experimental procedure. No anticoagulant was employed in the animals (with
the exception of the coronary hypoperfusion studies). By simultaneously sampling arterial and coronary sinus blood and determining coronary sinus blood flow (by the $^{[125]}\text{i}$ iodoantipyrine method (2)) the uptake and oxidation of FFA and myocardial removal of lactate and oxygen were determined (1).

Details of the methodology dealing with the endotoxin experiments, hemorrhagic hypotension, lactate infusion, and the coronary hypoperfusion studies have already been published (3-6). Anaphylaxis was produced in dogs by intravenous injection of horse serum which followed by 3 weeks the sensitization of the animals with horse serum. Physostigmine was infused intravenously and the dosage was adjusted to produce approximately 50% decrease of the mean arterial blood pressure. Details of the latter two groups of studies will be published.

RESULTS AND DISCUSSION

Administration of E. coli Endotoxin

After the administration of E. coli endotoxin in anesthetized dogs the following hemodynamic changes were obtained: mean arterial blood pressure decreased markedly (by 45%), heart rate decreased, and coronary sinus blood flow showed a tendency to decrease (Table 1). At the same time arterial FFA concentration did not change significantly, whereas the extraction ratio ($E$) \(\frac{\text{arteriovenous concentration}}{\text{arterial concentration}} \times 100\) decreased significantly. Myocardial FFA uptake and oxidation decreased (Table 2). During endotoxic shock the arterial lactate concentration was markedly elevated, lactate extraction ratio was decreased, and lactate removal by the myocardium was significantly increased (Table 3). Thus, the major changes can be summarized by stating that the contribution of FFA oxidation to myocardial oxidative metabolism decreased and the contribution of lactate increased after the administration of E. coli endotoxin (Table 4). At the same time
TABLE 1. Hemodynamic changes after E. coli endotoxin (n=6)\(^a\)

<table>
<thead>
<tr>
<th></th>
<th>Control(^b)</th>
<th>Change after(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100-140 min</td>
</tr>
<tr>
<td>Mean arterial blood pressure (mm Hg)</td>
<td>122 ±6</td>
<td>-57(^d) ±6</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>201 ±10</td>
<td>-28(^e) ±11</td>
</tr>
<tr>
<td>Coronary sinus blood flow (ml/100 g • min)</td>
<td>106 ±11</td>
<td>-15 ±9</td>
</tr>
</tbody>
</table>

\(^a\) Data reproduced from Spitzer et al. (3) by courtesy of the American Journal of Physiology.
\(^b\) Mean ± SE.
\(^c\) Mean difference ± SE.
\(^d\) p<0.01.
\(^e\) p<0.05.

TABLE 2. Changes in myocardial FFA metabolism after E. coli endotoxin (n=6)\(^a\)

<table>
<thead>
<tr>
<th></th>
<th>Control(^b)</th>
<th>Change after(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arterial FFA (umole/ml)</td>
<td>0.659 ±0.093</td>
<td>-0.001 ±0.107</td>
</tr>
<tr>
<td>FFA E%</td>
<td>53.0 ±4.6</td>
<td>-19.3(^d) ±4.8</td>
</tr>
<tr>
<td>FFA uptake (umole/100 g • min)</td>
<td>23.5 ±4.1</td>
<td>-11.0(^d) ±3.4</td>
</tr>
<tr>
<td>FFA oxidation (umole/100 g • min)</td>
<td>19.3 ±2.5</td>
<td>-13.4 ±3.6</td>
</tr>
</tbody>
</table>

\(^a\) Data reproduced from Spitzer et al. (3) by courtesy of American Journal of Physiology.
\(^b\) Mean ± SE.
\(^c\) Mean difference ± SE.
\(^d\) p<0.01.
TABLE 3. Changes in myocardial lactate uptake after *E. coli* endotoxin (n=6) \(^a\)

<table>
<thead>
<tr>
<th></th>
<th>Control 100-140 min</th>
<th>170-250 min</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arterial lactate</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(µmole/ml)</td>
<td>1.312 +3.464(^d)</td>
<td>+3.666(^d)</td>
</tr>
<tr>
<td></td>
<td>±0.239 ±0.668</td>
<td>±0.853</td>
</tr>
<tr>
<td><strong>Lactate E%</strong></td>
<td>37.9 ±5.9</td>
<td>-14.4(^e)</td>
</tr>
<tr>
<td></td>
<td>±10.5 ±4.8</td>
<td>±5.6</td>
</tr>
<tr>
<td><strong>Lactate uptake</strong></td>
<td>48.5 ±10.5</td>
<td>+39.3(^d)</td>
</tr>
<tr>
<td>(µmole/100 g min)</td>
<td>±12.6 ±11.5</td>
<td>±11.5</td>
</tr>
<tr>
<td><strong>Arterial glucose</strong></td>
<td>5.73 ±5.9</td>
<td>-1.51(^e)</td>
</tr>
<tr>
<td>(µmole/ml)</td>
<td>±0.56 ±0.32</td>
<td>±0.32</td>
</tr>
</tbody>
</table>

\(^a\) Data reproduced from Spitzer et al. (3) by courtesy of American Journal of Physiology.

\(b\) Mean ± SE.

\(c\) Mean difference ± SE.

\(d\) \(p<0.01\).

\(e\) \(p<0.05\).

TABLE 4. Contributions of FFA and lactate to myocardial CO\(_2\) production (n=6) \(^a\)

<table>
<thead>
<tr>
<th></th>
<th>Control 100-140 min</th>
<th>170-250 min</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FFA (%)</strong></td>
<td>76 ±12</td>
<td>-53(^d)</td>
</tr>
<tr>
<td></td>
<td>±13 ±11</td>
<td>±11</td>
</tr>
<tr>
<td><strong>Lactate (%)</strong></td>
<td>30 ±4</td>
<td>+35(^e)</td>
</tr>
<tr>
<td></td>
<td>±12 ±12</td>
<td>±12</td>
</tr>
<tr>
<td><strong>Myocardial RQ</strong></td>
<td>0.78 ±0.04</td>
<td>+0.16(^e)</td>
</tr>
<tr>
<td></td>
<td>±0.06 ±0.06</td>
<td>±0.06</td>
</tr>
</tbody>
</table>

\(^a\) Data reproduced from Spitzer et al. (3) by courtesy of American Journal of Physiology.

\(b\) Mean ± SE.

\(c\) Mean difference ± SE.

\(d\) \(p<0.01\).

\(e\) \(p<0.05\).
myocardial respiratory quotient (RQ) was significantly elevated reflecting the shift from fatty acid oxidation to lactate utilization.

It should be noted that the oxidation of FFA was directly determined from the conversion of $^{14}$C-labeled $\text{CO}_2$. At the same time lactate uptake rather than direct oxidation was determined in these studies. Equating oxidation with the uptake of lactate by the myocardium implies the assumption that all of the lactate removed was oxidized by this organ. This seems to be the case, as shown by earlier studies of Griggs et al. (7) and also by our own unpublished observations which indicate that 92 to 97% of the lactate removed is oxidized by the myocardium.

It may be noted that after the administration of endotoxin, the arterial glucose concentration decreased. We have noted such hypoglycemia in our earlier studies (8) and it has been demonstrated subsequently by Hinshaw et al. (9) that hypoglycemia may contribute to lethality after endotoxin shock.

It is of interest to re-emphasize two additional points (3): there was no evidence of myocardial hypoxia in these investigations, and the observed alterations of myocardial substrate utilization occurred very soon after the administration of endotoxin and preceded the changes of myocardial function by several hours.

**Hemorrhagic Hypotension**

Changes of myocardial substrate utilization after an acute severe hemorrhage were very similar to those noted during endotoxic shock. Under these conditions the mean arterial blood pressure decreased by 45%. After hemorrhage, FFA ceased to be the major metabolite oxidized by the myocardium. The contribution of lactate to myocardial energy metabolism increased markedly (Table 5).
TABLE 5. Contributions of FFA, triglyceride fatty acid (TGFA), and lactate to myocardial CO₂ production (n=9)

<table>
<thead>
<tr>
<th></th>
<th>Controlb</th>
<th>After hemorrhage</th>
<th>Changeo</th>
</tr>
</thead>
<tbody>
<tr>
<td>FFA (%)</td>
<td>58.5 ±11.7</td>
<td>18.4 ±7.9</td>
<td>-40.1d ±7.9</td>
</tr>
<tr>
<td>TGFA (%)</td>
<td>9.1 ±2.6</td>
<td>2.9 ±3.7</td>
<td>-6.2 ±3.7</td>
</tr>
<tr>
<td>Lactate (%)</td>
<td>33.1 ±10.3</td>
<td>68.5 ±15.3</td>
<td>+35.4e ±15.3</td>
</tr>
</tbody>
</table>

aData reproduced from Spitzer and Spitzer (4) by courtesy of American Journal of Physiology.

b Mean ± SE.

c Mean difference ± SE.
d p<0.01.
e p<0.05.

TABLE 6. Changes in myocardial lactate metabolism during anaphylactic shock (n=4)

<table>
<thead>
<tr>
<th></th>
<th>Controla</th>
<th>5-15 min</th>
<th>35-65 min</th>
<th>70-130 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arterial lactate (μmole/ml)</td>
<td>0.789 ±0.216</td>
<td>+1.568 ±0.466</td>
<td>+3.227 ±0.452</td>
<td>+3.118 ±0.901</td>
</tr>
<tr>
<td>Lactate extraction (%)</td>
<td>24.3 ±3.5</td>
<td>+2.6 ±3.7</td>
<td>+0.2 ±3.6</td>
<td>+0.7 ±2.8</td>
</tr>
<tr>
<td>Lactate uptake (μmole/min • 100 g)</td>
<td>19.2 ±5.7</td>
<td>+27.0 ±13.8</td>
<td>+68.8 ±19.0</td>
<td>+69.0 ±31.2</td>
</tr>
<tr>
<td>Myocardial RQ</td>
<td>0.80 ±0.02</td>
<td>-0.03 ±0.06</td>
<td>+0.19 ±0.05</td>
<td>+0.15 ±0.03</td>
</tr>
</tbody>
</table>

a Mean ± SEM.
Anaphylactic Shock

This condition was evoked by a challenging dose of horse serum given intravenously to dogs that had been sensitized with the same agent 3 to 4 weeks before the experiments. In these preliminary studies (thus the small number of experiments) the hemodynamic changes were comparable with those which occurred during the other two experimental conditions, e.g., mean arterial blood pressure decreased by 43%, cardiac output by 39%. Arterial lactate concentration again increased markedly after challenge and the uptake of this metabolite by the myocardium was elevated. Myocardial RQ also increased significantly (Table 6).

Infusion of Physostigmine

A group of experiments was performed in which physostigmine was administered in sufficient quantity to decrease the arterial blood pressure by approximately 50% (the decrease in mean arterial blood pressure was 55%). Under these conditions, the metabolic alterations were very similar to those that were obtained by studying the above three models. The percentage contribution of lactate to CO₂ production increased from 27% to 75%, and the myocardial RQ also increased (Table 7).

At this point, this question may be asked: what are the possible factors responsible for the changes in myocardial substrate utilization that are common among the various shock models? At least two of these may be noted, increased arterial lactate concentration and decreased coronary perfusion. Both of these conditions were, therefore, subjected to further studies.

Hyperlactacidemia due to Lactate Infusion

When L(+) lactate was administered intravenously into normal dogs in sufficient amounts to raise the arterial concentration markedly, it was found that the changes in myocardial substrate utilization resembled those observed
### TABLE 7. Effect of physostigmine infusion on myocardial metabolism (n=9)

<table>
<thead>
<tr>
<th></th>
<th>Controla</th>
<th>Infusion</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>60-105 min</td>
<td>120-165 min</td>
<td></td>
</tr>
<tr>
<td>FFA oxidation</td>
<td>15.6</td>
<td>3.6b</td>
<td>5.0c</td>
<td></td>
</tr>
<tr>
<td>(µmole/min · 100 g)</td>
<td>±3.5</td>
<td>±0.7</td>
<td>±1.9</td>
<td></td>
</tr>
<tr>
<td>Lactate uptake</td>
<td>35.3</td>
<td>49.2</td>
<td>39.3</td>
<td></td>
</tr>
<tr>
<td>(µmole/min · 100 g)</td>
<td>±8.3</td>
<td>±9.8</td>
<td>±11.7</td>
<td></td>
</tr>
<tr>
<td>Contribution to myocardial CO₂ production by FFA</td>
<td>70.8</td>
<td>44.0</td>
<td>34.2c</td>
<td></td>
</tr>
<tr>
<td>(µmole/min)</td>
<td>±13.1</td>
<td>±12.8</td>
<td>±9.6</td>
<td></td>
</tr>
<tr>
<td>Lactate (%)</td>
<td>26.5</td>
<td>75.1b</td>
<td>49.9c</td>
<td></td>
</tr>
<tr>
<td></td>
<td>±5.7</td>
<td>±7.1</td>
<td>±10.1</td>
<td></td>
</tr>
<tr>
<td>Myocardial RQ</td>
<td>0.79</td>
<td>0.93c</td>
<td>0.91c</td>
<td></td>
</tr>
<tr>
<td></td>
<td>±0.04</td>
<td>±0.05</td>
<td>±0.05</td>
<td></td>
</tr>
</tbody>
</table>

aMean ± SEM.
bp<0.01.
cp<0.05.

### Table 8. Effect of prolonged coronary hypotension on myocardial metabolism (n=10)

<table>
<thead>
<tr>
<th></th>
<th>1st Controlb</th>
<th>4 hr hypotension (change)</th>
<th>2nd Controlc</th>
</tr>
</thead>
<tbody>
<tr>
<td>FFA oxidation</td>
<td>2.3</td>
<td>+0.5</td>
<td>4.1</td>
</tr>
<tr>
<td>(µmole/min)</td>
<td>±0.6</td>
<td>±1.1</td>
<td>±1.3</td>
</tr>
<tr>
<td>Lactate uptake</td>
<td>38.9</td>
<td>-20.1c</td>
<td>31.6</td>
</tr>
<tr>
<td>(µmole/min)</td>
<td>±3.7</td>
<td>±4.1</td>
<td>±6.3</td>
</tr>
<tr>
<td>O₂ uptake</td>
<td>194</td>
<td>-56c</td>
<td>195</td>
</tr>
<tr>
<td>(µmole/min)</td>
<td>±13</td>
<td>±8</td>
<td>±14</td>
</tr>
<tr>
<td>Myocardial RQ</td>
<td>0.95</td>
<td>-0.06c</td>
<td>0.87</td>
</tr>
<tr>
<td></td>
<td>±0.01</td>
<td>±0.02</td>
<td>±0.04</td>
</tr>
</tbody>
</table>

aData reproduced from Spitzer et al. (6) by courtesy of American Journal of Physiology.
bMean ± SEM.
cp<0.01.
during experimental shock, although only minor changes in mean arterial blood pressure (-11%) were seen. The metabolic changes are seen in Figure 1 and indicate the decreased contribution of lactate utilization to myocardial CO$_2$ production. Myocardial RQ changes are also in accordance with these changes.

**Coronary Hypoperfusion Studies**

Experimentally produced hypoperfusion of the coronary vessel was the final condition investigated. For this preparation the method of Hinshaw et al. (10) was utilized in which the donor dog perfused in vitro the left ventricle of another dog's heart. The metabolic conditions during the control period (with afterload of 100 mmHg) were compared with those obtained during the hypoperfusion (at an afterload of 50 mmHg) for 4 hours. Studies of substrate utilization under these conditions indicated that myocardial FFA oxidation did not change significantly, although oxygen consumption, lactate utilization, and RQ decreased (Table 8). Thus, the contribution of lactate to myocardial energy metabolism decreased under these conditions.

In conclusion, these studies point out the alterations of substrate utilization by the myocardium during experimentally produced shock. These changes consisted of an increase in the importance of lactate with the simultaneous decrease of the importance of FFA as oxidizable substrates. The data further emphasize the key role that arterial lactate concentration plays in regulating substrate utilization by the myocardium.
REFERENCES


MYOCARDIAL SUBSTRATE UTILIZATION IN EXPERIMENTAL SHOCK

It has been demonstrated by numerous investigations that under control postprandial conditions the myocardium may utilize a variety of substrates. Quantitatively, the most important of these are fatty acids and lactate. Under control conditions close to two-thirds of the myocardial energy is derived from oxidation of free fatty acids (FFA) and about one-third from the utilization of lactate. Since the arterial concentration of several metabolites changes during shock, and because of the dependence of myocardial substrate utilization on arterial concentration, it seemed desirable to study the alterations in myocardial substrate utilization during experimentally produced shock.

The results obtained in several shock models are summarized in this presentation. The following interventions were utilized to produce shock-like conditions experimentally: (a) administration of an LD90 Escherichia coli endotoxin, (b) acute severe hemorrhage, (c) anaphylactic shock caused by horse serum administration, (d) severe hypotension caused by physostigmine infusion, (e) hyperlactacidemia caused by lactate infusion, and (f) prolonged hypoperfusion of the coronary arteries.
<table>
<thead>
<tr>
<th>Number of Copies</th>
<th>Details</th>
</tr>
</thead>
</table>
| (12)            | Administrator, Defense Documentation Center  
|                 | Cameron Station  
|                 | Alexandria, Virginia  22314 |
| (6)             | Director, Naval Research Laboratory  
|                 | Attention: Technical Information Division  
|                 | Code 2627  
|                 | Washington, D. C.  20375 |
| (6)             | Director, Naval Research Laboratory  
|                 | Attention: Library Code 2029 (ONRL)  
|                 | Washington, D. C.  20375 |
| (3)             | Office of Naval Research  
|                 | Medical and Dental Sciences  
|                 | Code 444  
|                 | Arlington, Virginia  22217 |
| (1)             | Commanding Officer  
|                 | Naval Medical Research and Development Command  
|                 | National Naval Medical Center  
|                 | Bethesda, Maryland  20014 |
| (1)             | Chief, Bureau of Medicine and Surgery  
|                 | Department of the Navy  
|                 | Washington, D. C.  20375 |
| (2)             | Technical Reference Library  
|                 | Naval Medical Research Institute  
|                 | National Naval Medical Center  
|                 | Bethesda, Maryland  20014 |
| (1)             | Office of Naval Research Branch Office  
|                 | 495 Summer Street  
|                 | Boston, Massachusetts  02210 |
(1) Office of Naval Research Branch Office  
536 South Clark Street  
Chicago, Illinois 60605

(1) Office of Naval Research Branch Office  
1030 East Green Street  
Pasadena, California 91101

(1) Office of Naval Research  
Contract Administrator for Southeastern Area  
2110 G Street, N.W.  
Washington, D. C. 20037

(1) Commanding Officer  
Naval Medical Research Unit No. 2  
Box 14  
APO San Francisco 96263

(1) Commanding Officer  
Naval Medical Research Unit No. 3  
PPO New York 09527

(1) Officer in Charge  
Submarine Medical Research Laboratory  
Naval Submarine Base, New London  
Groton, Connecticut 06342

(1) Scientific Library  
Naval Medical Field Research Laboratory  
Camp Lejeune, North Carolina 28542

(1) Scientific Library  
Naval Aerospace Medical Research Institute  
Naval Aerospace Medical Center  
Pensacola, Florida 32512

(1) Commanding Officer  
Naval Air Development Center  
Attn: Aerospace Medical Research Department  
Warminster, Pennsylvania 18974

(1) Scientific Library  
Naval Biomedical Research Laboratory  
Naval Supply Center  
Oakland, California 94625
(1) Commander, Army Research Office
     P. O. Box 12211
     Research Triangle Park
     North Carolina  27709

(1) Director, Life Sciences Division
     Air Force Office of Scientific Research
     1400 Wilson Boulevard
     Arlington, Virginia  22209

(1) Commanding General
     Army Medical Research and Development Command
     Forrestal Building
     Washington, D. C.  20314

(1) Department of the Army
     U. S. Army Science and Technology Center - Far East
     APO San Francisco  96328

(1) Assistant Chief for Technology
     Office of Naval Research, Code 200
     Arlington, Virginia  22217